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O R I G I N A L  R E S E A R C H
Outcomes and quality of life issues in the
pharmacological management of benign
prostatic hyperplasia (BPH)
Angelo J Cambio
Christopher P Evans
Department of Urology [A.J.C.,
C.P.E.], University of California,
Davis, Sacramento, CA, USA
Background: Benign prostatic hyperplasia (BPH) is a common disease of the aging male
population. BPH treatment includes a variety of pharmacological and surgical interventions. The
goal of this paper is to review the natural history of BPH, outcomes of pharmacological management,
effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused
perspectives.
Materials and methods: Medline searches for the keywords benign prostatic hyperplasia,
BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. Relevant literature
was reviewed and analyzed.
Results: Alpha blockers, 5 alpha-reductase inhibitors, and phytotherapy are the three categories
of pharmaceutical interventions currently available for BPH. Various clinical trials have shown
that alpha blockers and 5 alpha-reductase inhibitors are safe, efficacious, and improve QoL in
patients with BPH. The evidence for phytotherapeutics is not as convincing. The current
armamentarium of pharmaceutical interventions are encompassed in these three classes of
medications. New pharmacotherapies based on novel mechanisms are on the horizon.
Conclusion: There are a variety of safe and efficacious medical therapies available for the
management of BPH and it is important for the practicing physician to have an understanding of
these pharmacotherapies and their potential impact on the patient. There is not enough evidence to
make a recommendation regarding phytotherapy use. New classes of drugs for BPH will likely
find their way into routine use.
Keywords: Benign prostatic hyperplasia, benign prostatic hypertrophy, BPH, alpha blockers, 5
alpha-reductase inhibitor, quality of life.
Introduction
Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in US males.
Seventy-five percent of men in their seventh decade of life are affected (Wei et al
2005). In 2000, approximately 8 million office visits were accounted for by a primary
or secondary diagnosis of BPH (Wei et al 2005). The number of office visits for BPH
has recently increased, while the number of surgical interventions has decreased. This
shift reflects the increased selection and availability of effective pharmacologic
therapies (Wei et al 2005).
BPH: Assessing quality of life
Validated symptom scoring questionnaires
Lower urinary tract symptoms (LUTS) can be related to BPH, and the degree of symptom
severity dictates the impact on quality of life (QoL). Consistent and reliable evaluation
of patient symptoms is necessary to quantify symptoms and determine treatment efficacy.
To achieve this, various validated symptom scoring questionnaires have been designed
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and tested for consistency and reliability. These symptom
scores are useful for both clinical and research assessments
of medication efficacy.
Clinical research, some of which utilizes validated
questionnaires, is the foundation for evidence-based
medicine. The type of trial design contributes to the quality
of the data it yields (Ok et al 2005). Listed from most reliable
to least reliable, systematic reviews and meta-analyses of
randomized controlled trials (RCTs), nonrandomized
controlled trials, case reports, clinical examples, and
consensus meetings, are the different types of available
evidence (McAlister et al 1999).  Although evidence in the
published literature has differing levels of importance, it can
all play a role in patient management  (Smith and Somerfield
1997).
The most widely used and extensively validated
symptom score assessment is the American Urological
Association Symptom Index (AUASI) (Barry et al 1992;
MacDonald and McNicholas 2003). The AUASI is composed
of seven questions regarding incomplete emptying,
frequency, intermittency, urgency, weakness of the urinary
stream, straining, and nocturia. The test-retest correlation for
this questionnaire is 0.92 (Barry et al 1992).
Various questionnaires have been developed to
quantitatively assess symptoms and QoL issues in BPH.
Examples of validated questionnaires include: the Maine
Medical Assessment Program score (Fowler et al 1988), the
Boyarsky score (Boyarsky et al 1976), the Madsen-Iversen
Score (Madsen and Iversen 1983), International Prostate
Symptom Score (IPSS) (AUASI plus one question regarding
QoL) (Cockett et al 1991) and the Danish Prostatic Symptom
Score (Hald et al 1991; Meyhoff et al 1993).
BPH: Natural history
Defining the natural history of BPH improves management
and risk stratification. Community-based longitudinal
studies and placebo arms of clinical trials have been used to
define the natural history of BPH. Both study types have
inherent limitations; however, the latter generally provides
less reliable data than a community-based longitudinal study
(Fong et al 2005a; Roberts et al 2005).
Surrogate endpoints of clinical progression are used to
define natural history. Urinary symptom score, prostate
volume, urinary flow rate, episodes of acute urinary retention
(AUR), prostate-specific antigen (PSA), post-void residual
(PVR), and surgery have been utilized as surrogate endpoints
of disease progression.
American Urological Association
Symptom Index
The Olmsted County trial is a community-based, prospective
cohort study initiated to define the natural history of BPH.
The study included 2115 randomly selected men between
the ages of 40 to 79 years from Olmsted County, Minnesota
(Sarma et al 2002). An age-associated worsening AUASI and
bother score was noted at baseline and last follow-up. The
greatest increase in symptom and bother scores occurred
during the seventh decade of life. Specifically, nocturia and
weak stream demonstrated the strongest association with
aging. All seven AUASI symptoms demonstrated significant
progression with time and age. Symptoms related to voiding
or obstruction were the most common, while symptoms
related to storage, irritation, or social embarrassment were
the most bothersome. These findings suggest a slowly
progressive natural history of BPH with acceleration in
symptom severity among individuals in their seventh decade
of life (Sarma et al 2002).
Prostate volume
The Olmsted County study also investigated prostate growth.
Prostate volume was determined in 631 men by transrectal
ultrasound. After seven years of follow-up, the annual change
in volume was 1.6% across all age groups (Rhodes, Girman,
et al 1999). Increasing growth rate was observed with
increasing age and baseline prostate volume (Rhodes,
Girman, et al 1999).
Berry and colleagues (1984) reported the prevalence and
growth rate of BPH with age by collecting data from 10 studies
accounting for over 1000 cadaveric prostate samples. Men
between the ages of 21 and 30 had an average prostate mass
of 20g. In the absence of BPH, the prostate remained at this
size. Prostates that develop BPH had a greater growth velocity
in men between 31 and 50 years of age (doubling time 4.5
years), while men between the ages of 51 and 70 had a slower
doubling time of 10 years, and men over 70 had doubling
times greater than 100 years. Eight percent of men in their
fifth decade of life were shown to have pathological BPH,
while half of men in their sixth decade of life were shown to
have the condition.
Peak urinary flow rate
Peak urinary flow rate is another surrogate endpoint for
clinical progression of BPH. The Olmsted County trial data
demonstrated an annual median peak urinary flow rate slope
of –2.1% (Roberts et al 2000). Rapid decline in peak urinary
Therapeutics and Clinical Risk Management 2007:3(1) 183
Outcomes and QoL issues in BPH
flow rate was associated with decreasing baseline flow rate,
and increasing baseline age, prostate volume and symptom
severity (p = 0.001).
Acute urinary retention
The Olmsted County trial data demonstrated increasing
incidence of AUR associated with age and severity of
symptoms. Decreased peak urinary flow rates indicated a four-
fold increased risk of AUR, and men with prostates greater
than 30 cc experienced a three-fold increase in risk. Risk of
AUR, within a five-year period, was 1.6% and 10% for men
aged 40–49 and 70–79 years, respectively (Jacobsen et al
1997). AUR is a painful episode with proven negative impact
on QoL. Risk factors for AUR and proven efficacy in
minimizing this risk are important patient and pharmaceutical
factors.
Prostate-specific antigen
Increasing PSA (Roehrborn et al 2001; Wright et al 2002) is
a risk factor for prostate enlargement and may be predictive
of risk of developing BPH (Roehrborn et al 2001; Fong
et al 2005a). PSA alone (sensitivity 75%, specificity 64%)
has been shown to be comparable with both expanded models
(PSA, urinary frequency and hesitancy, flow rate parameters,
and symptom problem index, sensitivity 72%, specificity
67%) and a scoring algorithm as a predictor of disease
progression defined by AUR episode (Roehrborn et al 2001).
Although both PSA and prostate volume can be assessed
for risk of progression, PSA is more reliable and cheaper
than assessing prostate volume with digital rectal exam,
transrectal ultrasound, or magnetic resonance imaging (Fong
et al 2005a).
Post-void residual
The Olmsted County Study data has also been used to
describe the natural history of PVR and voided volume in
529 community dwelling men between the ages of 40 to 79
(Rule et al 2005). Median annual change in PVR was 2.2%
and voided volume was –2.1%. These data suggest gradually
increasing PVR and decreasing voided volume; however a
clear association has not yet been established between PVR,
voided volume, and lower urinary tract symptoms (LUTS).
Degree of LUTS and impact on QoL drive the
management of BPH. These measures of BPH aid in
quantifying such symptoms and associating them with
impact on QoL. Table 1 summarizes the natural history of
BPH as defined by measures of BPH.
BPH: Pharmacological therapy
Available pharmacotherapies for BPH fall under two general
categories––pha blockers and 5 alpha-reductase inhibitors.
Herbal remedies, while not regulated by the Food and Drug
Administration (FDA), are widely available and commonly
used.
Alpha adrenergic blockers: Mechanism
of action
Alpha blockers are adrenergic receptor antagonists. In the
lower urinary tract, these receptors are found in the smooth
muscle of the prostate, urethra, and bladder neck (Caine
1986). Adrenergic blockade results in relaxation of smooth
muscle at these anatomic locations, thereby allowing a wider
caliber outlet for the passage of urine.
There are two subtypes of alpha adrenergic receptor
associated with prostatic smooth muscle, alpha-1 and alpha-2
(Berthelson S 1977). Antagonism of the alpha-1 subtype has
shown clinical advantages in treating BPH and has thus been
the focus of subsequent study. Adrenoceptor research led to
the discovery, classification, and subdivision of type-1 alpha
receptors into the subtypes 1A, 1B, and 1D (Andersson et al
1997; Roehrborn and Schwinn 2004).
Phenoxybenzamine, prazosin, terazosin, doxazosin,
alfuzosin, and tamsulosin are alpha blockers currently
available for the treatment of BPH. Alpha blocker receptor
subtype selectivity, dose, and duration of action are
summarized in Table 2.
Phenoxybenzamine is not selective for alpha-1 versus
alpha-2 adrenergic receptor. Prazosin, terazosin, doxazosin,
and alfuzosin are selective for the alpha-1 receptor, but are
not subtype selective (Forray et al 1994; Andersson et al
1997; Roehrborn and Schwinn 2004). Tamsulosin has a
relatively greater affinity for the alpha-1A adrenergic receptor
in comparison with the 1B, and no selectivity for the alpha-1A
versus 1D receptor subtype (Forray et al 1994; Foglar et al
1995; Richardson et al 1997; Roehrborn and Schwinn 2004).
Alpha adrenergic blockers: safety and
efficacy
Multiple, large, randomized, placebo-controlled trials have
supported the safety and efficacy of alpha adrenergic blockers
for the treatment of BPH (Abrams et al 1995; Gillenwater
et al 1995; Chapple et al 1996; Lepor et al 1996; Roehrborn
et al 1996; Abrams et al 1997; Narayan and Tewari 1998;
Djavan and Marberger 1999; Narayan et al 2003; Roehrborn
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et al 2003). Table 3 summarizes clinical outcomes for some of
the large clinical trials of alpha blockers.
Phenoxybenzamine has proven efficacy in relieving
symptoms of BPH, but its use is limited by severe side-effects
(Caine et al 1976; Caine et al 1978). Approximately 30% of
patients experience side-effects related to phenoxy-
benzamine (Lepor 1990). Orthostatic hypotension is the main
adverse effect; however reflex tachycardia, nasal congestion,
diarrhea, miosis, sedation, nausea, and vomiting are also
associated (Walsh 2002). Interactions between phenoxy-
benzamine and other antihypertensive and/or vasodilatory
agents can cause additive hypotensive effects. Due to the
availability of alpha-1 selective agents, it is infrequently
prescribed for BPH.
Prazosin, an alpha-1 selective blocker, demonstrated
efficacy comparable with phenoxybenzamine without as
severe a side-effect profile (Hedlund et al 1983). However, a
first-dose phenomenon in which patients experience faintness,
dizziness, palpitation, and even syncope is associated with
prazosin use. The incidence of this side-effect can be minimized
with dose titration, as well as dosing before bed (Walsh 2002).
Terazosin has proven safety and efficacy in the treatment
of BPH. Large placebo-controlled trials have demonstrated
increased peak urinary flow, improved QoL and AUASI scores
Table 1 Natural history of BPH as measured by surrogate endpoints of AUASI, prostate volume, peak urinary flow, AUR, PSA,
PVR, and voided volume
Reference No Patients Surrogate endpoint
Sarma et al 2002 2115 AUASI Annual change in symptom score
40–79 years of age: +0.29 points per year
40–49 years of age: +0.13 points per year
60–69 years of age: +0.60 points per year
70–79 years of age: +0.38 points per year
Rhodes,Girman,et al 1999 631 Prostate volume % Annual change in prostate volume
Overall: +1.6%
Roberts et al 2000 492 Peak urinary flow % Annual change in peak urinary flow
40–79 years of age: –2.14%
40–49 years of age: –1.1%
>70 years of age: –6.2%
Prostate volume ≤30ml: –1.7%
Prostate volume >30ml: –3.0%
Jacobsen et al 1997 2115 AUR Risk of AUR within 5 years
40–49 years of age: 1.6%
70–79 years of age: 10%
Wright et al 2002 529 PSA Relative risk of prostate enlargement
Age Baseline PSA RR
40–49 ≥0.31 ng/mL 3–6-fold increase
50–59 ≥0.80 ng/mL 5–9-fold increase
60–69 ≥1.70 ng/mL 11-fold increase
Rule et al 2005 529 PVR Median annual % change PVR
40–79 years of age: 2.2
40–49 years of age: 1.8
50–59 years of age: 4.3
60–69 years of age: 2.6
70–79 years of age: –2.6
Rule 2005 529 Voided volume Median annual % change voided volume
40–79 years of age: –2.1
40–49 years of age: –1.3
50–59 years of age: –1.1
60–69 years of age: –4.3
70–79 years of age: –4.6
Abbreviations: AUASI, American Urological Association Symptom Index; AUR, acute urinary retention; BPH, benign prostatic hypertrophy;
PSA, prostate-specific antigen; PVR, post-void residual.
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versus placebo (Lepor 1995; Elhilali et al 1996; Roehrborn et
al 1996; Rhodes, Krogh et al 1999) The most common adverse
events are dizziness and asthenia with respective occurrence
rates of 6.7% to 19.8% and 3.8% to 12.3% (Lepor 1995; Elhilali
et al 1996; Roehrborn et al 1996). Sixteen percent of patients
on terazosin versus 11% on placebo
(p < 0.05) withdrew from the Hytrin Community Assessment
Trial (n = 2084) because of treatment emergent adverse events
(Roehrborn et al 1996). Overall, placebo-controlled trials
suggest that terazosin is effective in reducing symptoms of
BPH and improving QoL in patients with LUTS. However,
some patients will not tolerate terazosin and may benefit
from alternate pharmacotherapy.
Doxazosin has proven safety and efficacy in the treatment
of BPH (Chapple et al 1994; Fawzy et al 1995; Lepor et al
1997; de Reijke and Klarskov 2004). It has also been shown
to decrease blood pressure in hypertensive patients, while
not effecting normotensive patients (Kirby 1995). However,
the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) (ALLHAT 2000) was a
large, randomized, double-blind, active-controlled trial
designed to detect differences in major cardiovascular events
in hypertensive patients randomized to chlorthalidone,
doxazosin, amlodipine, or lisinopril. The doxazosin arm of
this trial was closed early due to a significantly higher
incidence of combined cardiovascular disease events,
particularly congestive heart failure (CHF) (ALLHAT 2000).
Prior to this study, alpha blockers were commonly an initial
drug choice for treating hypertension, particularly in patients
with coexisting BPH (JNC 1997); however, the ALLHAT trial
results demonstrated that the doxazosin group had an
increased risk of CHF and was less effective than
chlorthalidone at treating hypertension, resulting in multiple
medication use to control blood pressure. Also, more patients
discontinued doxazosin than chlorthalidone reflecting a
higher incidence of adverse events.
Alfuzosin has established short term safety and efficacy.
A systematic review included 11 trials and 3901 men,
particularly eight trials (n = 2381) compared alfuzosin with
placebo (mean duration 13 weeks, range 4 to 26 weeks)
(MacDonald and Wilt 2005), Six trials reported statistically
significant improvement in symptom scores in men receiving
alfuzosin versus placebo. Five trials reported significant
improvement in peak urinary flow over placebo. Two smaller
trials (n < 50) failed to show significant improvement in
symptoms or peak urinary flow. Dizziness was the most
commonly reported adverse event. Six percent of patients
withdrew from the study due to treatment-emergent adverse
events. Withdrawal rate was identical to placebo (MacDonald
and Wilt 2005). Results of this systematic review suggest
that alfuzosin is significantly efficacious in the treatment of
LUTS attributable to BPH. The identical rate of withdrawal
due to adverse events between alfuzosin and placebo suggest
that alfuzosin is safe and well tolerated by patients.
Tamsulosin has proven long-term safety and efficacy.
Narayan and colleagues (Narayan et al 2003) studied safety
and efficacy in 609 patients in a four-year multicenter study.
One hundred and nine patients in this trial had been on
tamsulosin for six years. Significant improvement from
baseline was maintained for as long as six years for total
AUASI score, QoL improvement, and peak urinary flow rate.
Adverse events accounted for 16% of patients discontinuing
Table 2 Alpha adrenergic receptor antagonists: subtype-selectivity, dosing, and duration of action
Medication Receptor subtype Tablet/capsule size Dosing schedule Duration of
(mg) action
Nonselective
Phenoxybenzamine α1 and α2 10 10 mg bid Long-acting
A1 selective
Alfuzosin α1A, α1B, α1D 2.5 2.5 mg tid Short-acting
Alfuzosin XL α1A, α1B, α1D 10 10 mg qd Long-acting
Prazosin α1A, α1B, α1D 2 2 mg bid Short-acting
Doxazosin α1A, α1B, α1D 1, 2, 4, 8 1, 2, 4, 8 mg qd Long-acting
Doxazosin GITS α1A, α1B, α1D 4, 8 4, 8 mg qd Long-acting
Terazosin α1A, α1B, α1D 1, 2, 5, 10 1, 2, 5, 10 mg qd Long-acting
A1 subtype-selective
Tamsulosin α1A, α1D 0.4 0.4, 0.8 Long-acting
Abbreviations: bid, twice daily; GITS, gastrointestinal therapeutic system; qd, once-daily; tid, three times daily; XL, extended-release.
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tamsulosin. Dizziness, postural hypotension, and syncope
were exceedingly rare with only 0.2% of patients
discontinuing tamsulosin for any one of these reasons. Less
than 1% of patients discontinued tamsulosin due to abnormal
ejaculation. Palacio and colleagues (Palacio et al 2004)
confirmed the safety and efficacy of tamsulosin in a
prospective multicenter trial including 2921 men with LUTS
suggestive of BPH and twelve months of follow-up. Six and
twelve month assessments demonstrated significant
improvement in the IPSS score, QoL, peak urinary flow,
irritative symptoms, and obstructive symptoms.
Prolonged release agents
Doxazosin use for BPH is limited by its first-dose side-effect
of hypotension. It requires a titration regimen that can require
up to four steps (Chung et al 1999). In response to this,
doxazosin gastrointestinal therapeutic system (GITS) was
developed. This controlled-release formulation has a more
gradual absorption and once-daily dosing that minimizes
adverse effects and may improve compliance (Chung et al
1999). Doxazosin GITS preserves efficacy, simplifies
titration and has a slightly better side-effect profile than the
standard titration (Kirby et al 2001).
Alfuzosin is currently available in an immediate-,
sustained-, and extended-release formulation with three
times, twice-, and once-daily dosage, respectively. The
extended-release preparation is equally effective as the
immediate release and has not been compared with the
sustained release formulation (Guay 2004). Food can effect
bioavailability of the extended-release formulation and
patients should be advised to take the medication on a full
stomach (Guay 2004). Also, hepatic impairment delays
elimination of alfuzosin, and therefore extended-release
formulations should be avoided in patients with this
condition (Guay 2004). Systematic review of clinical trials
for alfuzosin extended-release demonstrated a 4%
discontinuation rate. Treatment emergent adverse events
included dizziness (5.7%), headache (3%), and fatigue (2.7%)
(Guay 2004).
A new formulation of tamsulosin, oral-controlled
absorption system (OCAS), is expected to be available in the
near future. The current formulation is based on a controlled
release formulation and is prescribed as once-daily dosing
(Wyllie 2005). Tamsulosin should be taken 30 minutes after
the same meal each day to achieve steady serum levels over
a 24-hour period. The new OCAS formulation will likely
have altered bioavailability, onset of action and duration of
action relative to the current formulation (Wyllie 2005).
However, the active agent is the same and improved efficacy
should not be expected (Wyllie 2005). Given the already
convenient dosing and low incidence of adverse events with
the current formulation of tamsulosin, the motivation for
designing an extended-release formulation is unclear
(Wyllie 2005).
Alpha adrenergic blockers: sexual
side-effects
Alpha blockers have a low incidence of sexual side-effects.
However, they can cause reversible ejaculatory dysfunction
(Höfner et al 1999), in particular retrograde ejaculation. The
mechanism for sexual dysfunction relates to the antagonism
of the alpha receptors, located in the smooth muscle of the
bladder neck, preventing closure of the bladder neck, allowing
for retrograde ejaculation during climax (Carbone and
Hodges 2003).
In a review of 73 studies, sexual dysfunction associated
with BPH therapy was reported (Carbone and Hodges 2003).
The risk of retrograde ejaculation with transurethral resection
of the prostate (TURP) for BPH ranges from 25% to 99%. The
risk is 1% with alpha blockers, but can be higher with
tamsulosin (Carbone and Hodges 2003). This may be due to
alpha-1A receptors in the seminal vesicles that are blocked
by tamsulosin and thereby decrease the volume of ejaculate.
Tamsulosin has been reported to have an incidence of
ejaculatory disorder ranging from 4.5% (Chapple et al 1996)
to 30% (Narayan and Tewari 1998), however less than 1% of
patients discontinued tamsulosin for this reason (Lepor 1998;
Narayan and Tewari 1998; Höfner et al 1999; Schulman et al
2001; Narayan et al 2003). There is concern regarding the
QoL effects of ejaculatory dysfunction. Ejaculatory disorders
are viewed as a mild side-effect by patients and infrequently
result in discontinuation of therapy (Höfner et al 1999;
Narayan et al 2003; Lowe 2005).
Improved overall sexual function has been reported with
alpha blocker use (Lukacs et al 1996; Höfner et al 1999; van
Moorselaar et al 2005). This effect may be attributed to an
improved overall QoL, or possibly through a direct effect of
the alpha receptor antagonism (Lowe 2005). Urinary
symptoms associated with BPH are an independent risk factor
for sexual life dissatisfaction and severe symptoms have a
greater associated risk than moderate symptoms (Macfarlane
et al 1996; Vallancien et al 2003). Forty-six percent of patients
seen in urologic practice report that LUTS has a negative
impact on their sex lives (Frankel et al 1998).
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A direct relationship between alpha blockers and improved
sexual function has also been theorized. Alpha receptor
antagonism in the penis causes smooth muscle relaxation
resulting in relaxation of the lacunar spaces of the corpora
cavernosa, thereby potentially decreasing blood flow
resistance to erectile tissues and increasing erectile rigidity
(Andersson and Stief 1997; Höfner et al 1999; Lowe 2005).
Comparison of intracavernosal blood samples of healthy men
with those of patients with sexual dysfunction suggest that
somatic deregulation in sympathetic transmission, or changes
of catecholamine reuptake mechanisms, may play a role in
erectile dysfunction (Becker et al 2002). This mechanism
suggests another explanation regarding the efficacy of alpha
blockers in erectile dysfunction (Gwinup 1988; Becker et al
1998).
5 alpha-reductase inhibitors:
mechanism of action
Androgen suppression results in decreased prostate
volume and improvement in LUTS (McConnell 1990).
Dihydrotestosterone (DHT), a product of testosterone conversion
by the enzyme 5 alpha-reductase, has been shown to play a
role in the development of BPH (Coffey and Walsh 1990).
Finasteride is a 5 alpha-reductase inhibitor that effectively
inhibits DHT production. (Vermeulen et al 1989). There are
two isozymes of the 5 alpha-reductase enzyme, types I and II
(Jenkins et al 1992). Finasteride selectively inhibits only the
type II isozyme and it does not reduce DHT levels to those
seen in castration (Thigpen et al 1993).
Dutasteride, another 5 alpha-reductase inhibitor, differs
from finasteride in that it inhibits isozymes (Roehrborn et al
2002). Table 4 summarizes mechanism, dose, and adverse
effects associated with 5 alpha-reductase inhibitors.
5 alpha-reductase inhibitors:
safety and efficacy
The Proscar (Merck & Co., Inc., Whitehouse Station, NJ,
USA) Long-Term Efficacy and Safety Study (PLESS)
(McConnell et al 1998) included 3040 men with prostates
greater than 50g and BPH. After four years of finasteride
treatment, significantly reduced symptoms and prostate
volume, increased urinary flow rate, and reduced probability
of surgery and AUR were reported. There was a significant
difference noted in drug-related adverse events of decreased
ejaculate, ejaculation disorder, breast enlargement, breast
tenderness, and rash. Decreased libido and impotence only
retained significance versus placebo during the first year
of the trial.
Roehrborn and colleagues (Roehrborn et al 2002)
reported safety and efficacy results on 4325 men randomized
to either dutasteride or placebo in a multicenter, double-blind
trial with multiple interval assessments. Significant results
at 24 months of follow-up included: serum DHT reduction
by 90%, prostate volume reduction by 26%, and maximal
flow rate improvement of 2.2mL/s. Risk of AUR and surgical
intervention was reduced 57% and 48% versus placebo,
respectively. Two year open-label extension of this trial
suggests sustained and continued improvements in symptoms
and flow rate (Roehrborn et al 2005). Significant adverse
events included impotence, decreased libido, gynecomastia,
and ejaculation disorder. Only gynecomastia retained
significance, versus the placebo group, at 24 months. Table
5 summarizes safety and efficacy outcomes for 5 alpha-
reductase inhibitors.
Unlike alpha adrenergic blockers, the maximum efficacy
of 5 alpha-reductase inhibitors is not quickly achieved. Three
to six months of therapy is necessary to see maximum decrease
in prostate size and resultant improvement in LUTS (Peters
and Walsh 1987; Gormley et al 1992; McConnell et al 1998;
Bruskewitz et al 1999).
5 alpha-reductase inhibitors:
QoL and sexual side-effects
As part of the PLESS trial, Bruskewitz and colleagues
(Bruskewitz et al 1999) investigated the long-term effects of
finasteride on QoL in men with moderate-to-severe LUTS
secondary to BPH. This trial utilized a questionnaire focused
on degree of bother, lifestyle interference, and sexual issues.
After 4 years of follow-up, men receiving finasteride were
significantly (p < 0.01) less bothered by LUTS and had
Table 4 5 Alpha-reductase inhibitors: mechanism, dose, and
associated adverse effects
Drug Name Mechanism Dose Adverse effects
Finasteride Inhibits type 5mg qd decreased libido,
II isozyme impotence, decreased
ejaculate, ejaculation
disorder, breast
enlargement, breast
tenderness, and rash
Dutasteride Inhibits type 0.5mg qd impotence, decreased
I and type II libido, gynecomastia,
isozyme and ejaculation
disorder
Abbreviations: qd, once-daily.
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Table 5 Summary of 5 alpha-reductase inhibitor clinical trial outcomes for BPH
Significant changes in BPH
measurements TEAE
Peak % % patients
No. Study SI flow volume discontinuing‡ Most common
Reference Agent patients length Dose SI change (mL/s) change* medication TEAEs (%)
McConnell Finasteride 3040 48 mo 5mg AUASI** –2.6 1.9 –18 12 ED (8)
et al 1998 Decreased libido (6)
Decreased ejaculate
volume (4)
Ejaculation dysfct (1)
Roehrborn Dutasteride 2951 24 mo 0.5mg AUASI –4.5 2.2 –26 9 ED (7)
et al 2002 Decreased libido (4)
Gynecomastia (2)
Ejaculation dysfct (2)
Note: *% change in volume at one year; ‡percentage of patients discontinuing drug due to TEAE; ** “quasi-AUA score” was constructed from seven questions that
were part of a larger series of questions constructed before use of AUASI.
Abbreviations: AUASI, American Urological Association Symptom Index; ED, erectile dysfunction; mo, month; NS, not significant versus placebo; SI, symptom index;
TEAE, treatment-emergent adverse events.
significantly less activity interference and worry about urinary
function secondary to LUTS. Effects became evident after 4
months of treatment. Domains of sexual satisfaction and
sexual drive were worse for the finasteride group than the
placebo group, while no differences were found for the
question regarding erectile difficulty.
O’Leary and colleagues (O’Leary et al 2003) investigated
the effect of dutasteride on BPH-specific health status. This
randomized, double-blind, placebo-controlled study utilized
the BPH Impact Index (BII) validated questionnaire (Barry
et al 1995) in 4325 men with LUTS due to BPH to assess
quality of life. The BII is composed of four questions
addressing physical discomfort, worry, degree of bother, and
time away from regular activities due to urinary problems.
Dutasteride versus placebo resulted in significant
improvements in mean BII score after 6 months of therapy
with continued improvements from six months to two years.
This finding suggests that dutasteride, despite its known
sexual side-effects, improves QoL in patients with BPH.
The negative impact on sexual health is greater with 5
alpha-reductase inhibitors than alpha blockers (Lowe 2005).
The anti-androgen effects of finasteride and dutasteride
should be considered when choosing a pharmacologic
therapy for patients with BPH.
Combination therapy
As the two classes of drugs suggest, BPH symptoms respond
to both inhibition of sympathetic smooth muscle tone and
gland volume reduction. The distinct mechanisms of action
associated with the two drug classes suggest that combination
therapy may have added benefit when compared to either of
the two therapies alone.
Two trials, the Veterans Affairs Cooperative Studies Benign
Prostatic Hyperplasia Study (Lepor et al 1996), which
compared terazosin, finasteride, and combination therapy
with placebo, and the Prospective European Doxazosin and
Combination Therapy (PREDICT) (Kirby et al 2003) trial
which compared doxazosin, finasteride, and combination
therapy with placebo, failed to show any benefit of
combination therapy.
The Medical Therapy of Prostate Symptoms (MTOPS)
trial (McConnell et al 2003) was a multi-center, double-blind,
placebo-controlled clinical trial developed to compare the
efficacy of combination therapy with doxazosin and
finasteride with that of either therapy alone. 3047 men were
enrolled in the trial and follow-up was reported for an average
of 4.5 years (McConnell et al 2003). The results demonstrated
a significantly reduced risk of overall clinical progression
with combination therapy. This risk was defined as “An
increase above baseline of at least 4 points in the American
Urological Association Symptom Score, acute urinary
retention, urinary incontinence, renal insufficiency, or
recurrent urinary tract infection.” (McConnell et al 2003).
The reduction in risk of BPH progression associated with
combination therapy (66% for the combination vs placebo,
p < 0.001) was significantly greater than that associated with
doxazosin (p < 0.001) or finasteride (p < 0.001) alone
(McConnell et al 2003). The risks of AUR and the need for
invasive therapy were significantly reduced by combination
therapy and finasteride alone, but not by doxazosin alone.
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Combination therapy was superior to both doxazosin and
finasteride alone (McConnell et al 2003). Table 6 summarizes
clinical outcomes reported by the MTOPS trial. Dis-
continuation rates were 27% for doxazosin, 24% for
finasteride, and 18% for men who were receiving combination
therapy (McConnell et al 2003). Adverse events were the
most common reason for stopping treatment. The numbers of
statistically significant side-effects were 5, 3, and 9
for doxazosin, finasteride, and combination therapy,
respectively. Adverse events that occurred more frequently
with combination therapy versus either drug alone included:
abnormal ejaculation, peripheral edema, and dyspnea
(McConnell et al 2003). The definition of discontinuation
in the combined arm was discontinuation of both drugs, and
as such more patients in the combination arm may have been
on at least one drug as opposed to nothing. The intention to
treat design combined with drug tolerability and definition
of discontinuation could be contributing to the outcomes
reported (Ok et al 2005).
Phytotherapeutics
The annual prevalence of dietary supplement use in the US
increased from 14.2% in 1988–1999 to 18.8% in 2002 (Kelly
et al 2005). Dietary supplement use doubled for those age 65
years and older. Saw Palmetto is the second most commonly
used dietary supplement in men between the ages of 45 and
64, and fourth most commonly used in men aged 65 and
older (Kelly et al 2005).
Saw Palmetto
Saw palmetto (Serenoa repens) is derived from the American
dwarf palm tree berry, which naturally grows in the
southeastern US (Fong et al 2005b). It has been used as a
natural remedy for BPH. Although the mechanism of action
has not been completely defined, the most accepted
mechanism is 5 alpha-reductase inhibition (Fong et al 2005b).
Saw palmetto has been investigated in large, randomized,
placebo-controlled trials utilizing validated questionnaires
(Carraro et al 1996; Gerber et al 2001; Debruyne et al 2002;
Debruyne et al 2004). It has also been compared with
finasteride and tamsulosin (Carraro et al 1996; Debruyne
et al 2002). In a recent review of the literature regarding saw
palmetto, Fong and colleagues (Fong et al 2005b) concluded
that this phytotherapeutic significantly improves symptom
score (assessed with IPSS score) (Carraro et al 1996; Gerber
et al 2001; Debruyne et al 2002; Debruyne et al 2004), QoL
(Carraro et al 1996), and urinary flow rate (Carraro et al 1996;
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Debruyne et al 2002). Saw palmetto has been shown to have
a lower incidence of sexual dysfunction and ejaculatory
disorders than both alpha blockers and 5 alpha-reductase
inhibitors (Carraro et al 1996; Debruyne et al 2002).
Despite previous reports, results from a recent randomized,
placebo-controlled trial have called into question the efficacy
of saw palmetto. Bent and colleagues (Bent et al 2006)
randomized 225 men with moderate to severe BPH to one
year of treatment with saw palmetto extract or placebo. They
reported no significant difference between the groups in
change in AUASI score, maximal urinary flow rate, prostate
size, residual volume after voiding, QoL, or PSA during the
one-year study. The incidence of side-effects was similar
between the two groups. Table 7 summarizes the clinical
outcomes reported by Bent and colleagues (Bent et al 2006).
Unlike previous studies, this trial used a placebo that was
similar in appearance and smell to the pungent active agent.
Furthermore, the adequacy of blinding was validated.
Inadequate blinding may decrease response in a placebo
group, thereby artificially increasing the response in the
experimental group. Although this trial challenges current
belief that saw palmetto is somewhat efficacious in treating
BPH symptoms, reproduction of these results with a similar
well designed trial is necessary to confirm these findings.
Also, supplemental “prostate-health” preparations include
various herbal extracts other than saw palmetto. The other
extracts and the combined use of them may, or may not, alter
efficacy of such products. We feel that patients should be
made aware of the results of this trial so that they can make
informed decisions regarding the use of saw palmetto for
BPH symptoms.
Pygeum africanum
P. africanum is a plant extract derived from the African plum
tree that is widely used in Europe (Lowe and Fagelman 1999).
A systematic review and quantitative meta-analysis was
conducted to investigate the efficacy and tolerability of this
phytotherapeutic in men with BPH (Ishani et al 2000).
Eighteen RCTs accounting for 1562 subjects were analyzed.
Mean follow-up was 64 days. Six studies involving 474
subjects compared P. africanum with placebo. Men were twice
as likely to report an overall improvement of symptoms when
taking P. africanum extract versus placebo. Nocturia and
residual urine volume were reduced by 19% and 24%,
respectively. Peak urine flow was increased by 23%. Similar
to placebo (11%), 12% of patients dropped out of respective
studies. Adverse events were generally mild. Gastrointestinal
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side-effects were the most common. Although this report is a
meta-analysis, most of the included trials did not provide
clinically relevant baseline and outcomes data, none were
conducted in the US, no standardized validated symptom
scales were used, studies were of short duration, and outcomes
of acute urinary retention, renal insufficiency, or surgical
intervention were not considered (Ishani et al 2000).
A randomized, double blind study comparing once and
twice daily dosing of P. africanum investigated the safety,
efficacy, and QoL outcomes in the BPH patient (Chatelain
et al 1999). 174 patients completed the open phase of the
trial (100mg once daily) with follow-up of 12 months. IPSS
score improved 46% after 12 months. Thirty-two percent of
patients scored a 5 (unhappy) or a 6 (terrible) at baseline, and
only 11% indicated these poor QoL scores after 12 months.
After one year, 58% of patients indicated a QoL score of
“mostly satisfied, pleased, or delighted.” After two months,
peak urinary flow significantly improved and was maintained.
Prostate volume was significantly reduced by 7% after one
year. Similar to the meta-analysis, gastrointestinal side-effects
were the most common. Less than five percent of patients
withdrew from the trial secondary to side-effects. There were
no significant changes to PSA levels or sexual activity. This
trial suggests safety and efficacy for once a day dosing of
P. africanum for patients with BPH.
Less studied phytotherapies include Urtica dioica
(stinging nettle), Cucurbita pepo (pumpkin seed), opuntia
(cactus flower), Pinus (pine flower), Picea (spruce), and Secale
cereale (rye pollen). These agents are often part of
combination preparations formulated for “prostate health.”
Due to the lack of consistency of active agent dose and
knowledge regarding pharmacokinetic information and
possible drug interactions, we do not feel that there is enough
evidence to recommend these products; however in our
opinion it is important to be aware of the information that is
available regarding herbal remedies as their use is quite
common.
Differential review of agents used
in BPH therapy
In a meta-analysis, Djavan and Marberger (Djavan and
Marberger 1999) assessed whether or not alpha blockers could
be distinguished based on efficacy and/or tolerability. Both
placebo-controlled and comparison studies involving
alfuzosin, terazosin, doxazosin, and tamsulosin were
analyzed. Overall, the various alpha blockers produced
similar improvements in symptom scores and urinary flow
rates. Significant differences were found in side-effect profiles.
Based on study withdrawal rates due to adverse events and
incidence of vasodilatory adverse events, alfuzosin and
tamsulosin were better tolerated than terazosin or doxazosin.
Withdrawal rates for alfuzosin and tamsulosin were similar to
placebo at 4% to 10%. Fourteen percent to 20% of patients
taking terazosin or doxazosin withdrew from studies because
they could not tolerate related adverse effects. Also,
tamsulosin had less effect on blood pressure than alfuzosin
or terazosin.
The safety and efficacy of alfuzosin and tamsulosin
versus placebo has been studied. In a randomized, double-
blind, placebo-controlled study, 625 patients were
randomized to alfuzosin (10mg or 15mg), tamsulosin
0.4mg, or placebo for twelve weeks (Nordling 2005).
Results demonstrated significant improvement in IPSS
score for alfuzosin 10mg and tamsulosin versus placebo
(p = 0.007, p = 0.014, respectively), while alfuzosin 15mg
demonstrated a trend toward an improvement (p = 0.05).
Both doses of alfuzosin and tamsulosin produced a
significant increase in peak urinary flow relative to
placebo (p = 0.02). Alfuzosin and tamsulosin were well
tolerated. Dizziness was the most common adverse event
with 4%, 6%, 7%, and 2% of patients reporting this adverse
event for placebo, alfuzosin 10mg, alfuzosin 15mg, and
tamsulosin, respectively. Sexual function adverse events
were also low with 0%, 3%, 1%, and 8% incidence for
placebo, alfuzosin 10mg, alfuzosin 15mg, and tamsulosin,
respectively. Discontinuation rate (8%) was greatest with
alfuzosin 15mg. This study suggests that the greatest
benefit with minimized side-effects can be achieved with
the use of alfuzosin 10mg or tamsulosin.
BPH treatment strategies
The Triumph Project investigated treatment strategies,
patterns of drug use and treatment discontinuation in men
with BPH (Verhamme et al 2003). Nine percent of patients
newly diagnosed with BPH undergo surgery, while 45% are
treated pharmacologically within the first year after diagnosis
(Verhamme et al 2003). Age, type of complaint, and
co-morbidity are factors associated with receiving
pharmacologic therapy versus watchful waiting or surgery.
Alpha blockers are the most commonly prescribed first line
therapy (Verhamme et al 2003). Adherence rates of alpha
blockers (67% at one year) are similar to 5 alpha-reductase
inhibitors (73% at one year) and combination therapy (71%
at one year) (Verhamme et al 2003). Adherence rates do not
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vary within a class of medication (Verhamme et al 2003).
Patients with voiding symptoms (versus storage or post
micturition syndromes), younger age, normal PSA, and less
co-morbidity are more likely to discontinue medication
(Verhamme et al 2003). These treatment strategies reflect the
conservative nature of BPH management, safety of alpha
blockers and 5 alpha-reductase inhibitors, and risk
stratification for progressive disease.
One-quarter of patients discontinue pharmacologic
treatment early after starting (adherence time <20% of total
follow-up). Overall, the most common reasons for
discontinuing a medication are adverse events or persistence
of complaints despite therapy or resolution of complaint
(Verhamme et al 2003). Interestingly, adherence of once-daily
dosing preparations is not significantly better than multiple
dosing regimens (Verhamme et al 2003).
In practice, BPH treatment is largely based on patient
symptoms. Typically, we start with pharmacologic therapies
and advance to minimally invasive and ultimately surgical
options. Alpha blockers, particularly tamsulosin, are first line
agents for BPH treatment because they are effective with
limited side-effects and convenient once-daily dosing. If a
patient is unable to tolerate an alpha blocker or if the
medication is not efficacious we would offer a 5 alpha
reductase inhibitor or a minimally invasive therapy. 5 alpha-
reductase inhibitors are especially helpful in patients with
large prostate glands (>50 g) and/or symptomatic bleeding.
Long-term use of 5 alpha-reductase inhibitors is somewhat
controversial because of the associated increased rate of higher
grade prostate cancers. As discussed earlier, the evidence for
combination therapy is unclear and we do not routinely
recommend it due to a 2-fold increase in side-effects and
costs. Patients not desiring to take a medication are offered
minimally invasive or surgical options.
Discussion
Major events in the development and
progression of BPH
Patients suffering from LUTS secondary to BPH typically
experience the gradual onset of symptoms that can prompt
seeking of medical treatment. Also, AUR can rarely be the
presenting event. Without treatment, patients are at risk for
disease progression including AUR, recurrent urinary tract
infection, hydronephrosis, gross hematuria, bladder stones,
bladder decompensation, overflow incontinence, renal
impairment, and even renal failure can result. The impending
impact these events have on QoL justifies the need for
appropriate therapeutic intervention.
Critical issues in QoL
Critical issues in QoL management with these agents relate
to the subjective experience of the patient. Symptoms
attributed to BPH have been shown to negatively impact
QoL, therefore it is reasonable to treat these patients. However,
patients with low-to-moderate symptoms may not be bothered
enough to warrant medical intervention. These patients may
be best served by watchful waiting because treatment side-
effects may negate benefits of therapy.
Patients desiring medical treatment are at risk for adverse
events. Although the risk of side-effects with the current
agents is quite low, this risk can be minimized by starting
with alpha adrenergic antagonists, particularly tamsulosin,
and advancing to 5 alpha-reductase inhibitors.
Patients having persistent symptoms, despite alpha
blocker therapy, carry the combined risk of medication side-
effect and LUTS. These patients can be offered an alternate
alpha blocker, trial of a 5 alpha-reductase inhibitor or a
minimally invasive/surgical option.
Future directions and experimental
therapy
Outside of alpha adrenergic antagonism, 5 alpha-reductase
inhibition and phytotherapeutics there has not been
alternate drug classes for treatment of BPH. However, new
forms of monotherapy, as well as combination therapy with
alpha adrenergic antagonists, are on the horizon. Further
improvement of alpha adrenergic receptor subtype
selectivity (Barrow et al 2000), endothelin receptor
antagonists (Stachon et al 2004), phosphodiesterase
inhibitors, nitric oxide, cyclic guanosine monophosphate,
L-arginine, vanilloid receptor modulation, and purine
receptor modulation are future therapies for the treatment
of BPH (Andersson et al 2002).
Pharmacogenomics and BPH
The efficacy and tolerability of pharmaceutical agents vary
from person to person. This variability is believed to result in
part from the unique interaction of a pharmaceutical agent
with the genetic makeup of the individual.
Pharmacogenomics is the study of this interaction. The
science of pharmacogenomics is intended to produce
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medications individualized for one’s genetic makeup thereby
maximizing efficacy and tolerability.
While this line of research is still in its infancy, investigation
is underway to define the association of BPH and
polymorphisms of genes involved in sex hormone metabolism,
growth factors, cytokine and Vitamin D receptors (Mullan et
al 2006; Roberts et al 2006). Highly selective, efficacious
therapies with low side-effect profiles are anticipated to result
from pharmacogenomic research.
Conclusion
There are a variety of safe and efficacious medical therapies
available for the management of BPH and it is important for
the practicing physician to have an understanding of these
pharmacotherapies and their potential impact on the patient.
Due to the widespread use of phytotherapies, despite adequate
evidence of efficacy and safety, physicians must be aware of
existing evidence for these products. Particular patient
characteristics; of which age, symptom severity, co-morbidities,
and sexual function are only a few, should be considered
when devising a treatment plan for patients with BPH.
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